← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Illexcor Therapeutics, Llc
Richmond, VA
$5,644,047
Total funding
5
Grants
Funding over time
peak $1.7M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,644,047 · 5
By mechanism
R44$4,745,673 · 2
R43$898,374 · 3
Investigators at Illexcor Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$976,740
R44 · FY2023 · HL
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$887,907
R44 · FY2024 · HL
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$807,795
R44 · FY2024 · HL
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$798,351
R44 · FY2025 · HL
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$745,621
R44 · FY2023 · HL
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$529,259
R44 · FY2025 · HL
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$300,000
R43 · FY2020 · HL
Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease$299,962
R43 · FY2020 · HL
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$298,412
R43 · FY2021 · HL